The natural history of tolerance to the benzodiazepines
Abstract
Dependence on benzodiazepines following continued use is by now a well-documented clinical phenomenon. Benzodiazepines differ in their dependence potential. The present studies were aimed at examining the possibility that differential rates of tolerance development might account for differences in dependence risk. Four studies are reported. The first three studies concerned normal subjects. The development of tolerance over a fifteen day period was demonstrated for three different benzodiazepines (ketazolam, lorazepam and triazolam) using two paradigms. Tolerance in terms of a reduction in effectiveness of a repeated given dose was most notable for the benzodiazepine with a medium elimination half-life (lorazepam) for physiological, behavioural and subjective measures. In the case of the drug with the longest elimination half-life (ketazolam) reduction in effectiveness could only be assumed to be occurring if account was taken of the steady increase in plasma concentrations of active metabolites. For this drug it seemed that the physiological measures were those most likely to demonstrate the development of tolerance. Although triazolam showed few significant drug effects on this paradigm (testing being 12 hours after ingestion of this short half-life benzodiazepine), tolerance was seen to develop on some subjective measures. Using an alternative method of testing tolerance, assessing responses to a diazepam challenge dose, a high degree of tolerance on two-thirds of the measures was observed in subjects when pretreated with the benzodiazepine with the most marked accumulation of active metabolites (ketazolam). The other two drugs also led to tolerance development on a range of measures; this was more marked for lorazepam than triazolam. Blunting of the growth hormone response to diazepam was the most sensitive and reliable method of detecting tolerance to the benzodiazepines. Symptoms on discontinuation of the two weeks' intake of the benzodiazepines were marked for all the drugs but unrelated to either the tolerance induced or the elimination half-life of the particular drug. A further clinical study revealed that tolerance persisted in a group of long-term benzodiazepine users for between four months and two years following complete abstinence from the drug. These patients appeared to be less affected by diazepam in terms of its commonly observed subjective effects, regardless of their original medication. These ex-long-term users of benzodiazepines were, however, more likely to manifest two specific types of effects--immediate 'symptom' reduction and exacerbation of 'withdrawal symptoms' over the subsequent week.(ABSTRACT TRUNCATED AT 400 WORDS)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Higgitt 1988, former benzodiazepine patients had higher levels than controls of drowsiness, muscle cramps, impaired concentrations, eye soreness, and sadness.
“Former BZD patients had higher levels than controls of: drowsiness, muscle cramps, impaired concentrations, eye soreness, and sadness”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [39]
Cites
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972 · see citing works
Self-citationExperimental designs balanced for the estimation of residual effects of treatments
Williams, E. (1949) · Australian Journal of Scientific Research Series A Physical Sciences · doi:10.1071/ch9490149 · Cited by 1,104 · see citing works
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369 · see citing works
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297 · see citing works
Long-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.250.6.767 · Cited by 276 · see citing works
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176 · see citing works
Early Morning Insomnia with Rapidly Eliminated Benzodiazepines
Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (1983) · Science · doi:10.1126/science.6131538 · Cited by 138 · see citing works
Anxiety caused by a short-life hypnotic.
Morgan, K., & Oswald, I. (1982) · BMJ · doi:10.1136/bmj.284.6320.942 · Cited by 137 · see citing works
Development of tolerance to the anticonvulsant effect of diazepam in dogs
Frey, H.-H., Philippin, H.-P., & Scheuler, W. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90365-0 · Cited by 80 · see citing works
Lorazepam—Efficacy, side effects, and rebound phenomena
Scharf, M. B., & Jacoby, J. A. (1982) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1982.27 · Cited by 43 · see citing works
Long‐Term Comparison of Alprazolam, Lorazepam and Placebo in Patients with an Anxiety Disorder
Cohn, J. B., & Wilcox, C. S. (1984) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1984.tb03327.x · Cited by 28 · see citing works
Effects of lorazepam and its withdrawal on sleep, performance, and subjective state
Walsh, J. K., Schweitzer, P. K., & Parwatikar, S. (1983) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1983.203 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573 · see citing works
Self-citationDell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210 · see citing works
Self-citationTreatment of posttraumatic stress disorder: Focus on pharmacotherapy
Ehret, M. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.373 · Cited by 53 · see citing works
Fernandes, C., File, S. E., & Berry, D. (1996) · Brain Research · doi:10.1016/0006-8993(96)00644-0 · Cited by 30 · see citing works
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025) · PLOS One · doi:10.1371/journal.pone.0330277 · Cited by 7 · see citing works
- Authors
- Higgitt, A., Fonagy, P., & Lader, M.
- Affiliations
- St Mary's Hospital (GB)
- ORCID
- Fonagy, P.
- Venue
- Psychological Medicine. Monograph Supplement
- Publisher
- Cambridge University Press (CUP)
- Published
- 1988
- Volume
- 13
- Pages
- 1-55
- ISSN
- 0264-1801 (ISSN-L)
- 2051-2023
- OpenAlex
- W2120166535
- Cited by
- 37
- References
- 12
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 1 · 2014: 1 · 2012: 3
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychological Medicine Monograph Supplement (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- benzodiazepine dependence, lorazepam, triazolam, elimination half-life, bioactive metabolites, growth hormone response, withdrawal symptoms
- MeSH terms
- Adult, Affect, Arousal, Attention, Diazepam, Dose-Response Relationship, Drug, Drug Tolerance, Electroencephalography, Female, Humans, Long-Term Care, Male, Metabolic Clearance Rate, Risk Factors, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review